Full Name
Lisa DEROSA
Job Title
Medical Oncologist, Immunologist
Company
Gustave Roussy
Speaker Bio
Dr. Lisa Derosa, MD, PhD is a medical oncologist and clinician-scientist, currently an Associate Professor at the University of Paris-Saclay. She completed her specialization in Medical Oncology in 2014 at the University of Pisa (Italy), and pursued her scientific career at the University of Paris-Saclay, where she also earned a PhD in Immunology. She was appointed to the Faculty of Medicine at Paris-Saclay on September 1st, 2023.
Dr. Derosa serves as the Clinical Director of the Clinicobiome program at Gustave Roussy Cancer Campus (GRCC), the largest cancer center in Europe, where she leads translational and interventional research focusing on the role of the gut microbiota in cancer therapies. She also co-leads the national RHU program ImmunoLife and the European project Oncobiome.
A recognized expert in tumor immunology and cancer immunotherapy, Dr. Derosa was among the first to uncover the negative impact of antibiotic exposure and the composition of the gut microbiota on the efficacy of immune checkpoint inhibitors.
She has received numerous prestigious awards, including the ESMO Translational Research Award, and recognitions from ASCO, ESMO, European Urology, French National Academy of Medicine and other leading institutions. She is a Scientific Advisory Board member of everImmune, a biotech company dedicated to microbiota-based cancer therapies.
Dr. Derosa has authored over 100 publications indexed in PubMed, with an H-index of 45 and more than 15,000 citations. Her work has been featured in leading journals such as Nature Medicine, Cell, and Cancer Discovery, where she has contributed as first, last, or co-senior author.
Dr. Derosa serves as the Clinical Director of the Clinicobiome program at Gustave Roussy Cancer Campus (GRCC), the largest cancer center in Europe, where she leads translational and interventional research focusing on the role of the gut microbiota in cancer therapies. She also co-leads the national RHU program ImmunoLife and the European project Oncobiome.
A recognized expert in tumor immunology and cancer immunotherapy, Dr. Derosa was among the first to uncover the negative impact of antibiotic exposure and the composition of the gut microbiota on the efficacy of immune checkpoint inhibitors.
She has received numerous prestigious awards, including the ESMO Translational Research Award, and recognitions from ASCO, ESMO, European Urology, French National Academy of Medicine and other leading institutions. She is a Scientific Advisory Board member of everImmune, a biotech company dedicated to microbiota-based cancer therapies.
Dr. Derosa has authored over 100 publications indexed in PubMed, with an H-index of 45 and more than 15,000 citations. Her work has been featured in leading journals such as Nature Medicine, Cell, and Cancer Discovery, where she has contributed as first, last, or co-senior author.
Speaking At
